PharmaCyte Biotech Inc (PMCB)

[tulla236a]

i can't figure out why this was on pmcb facebook.

promoting cell therapies for austrianova? does kymriah need the ciab to protect it? are they preparing us for pc ciab to cost 1/2 million dollars per treatment?



PharmaCyte Biotech, Inc.

September 4 at 1:43pm ·
..

In a historic decision, last week the U.S. Food and Drug Administration approved the first engineered T-cell treatment for cancer, Kymriah.

“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” said FDA Commissioner Scott Gottlieb, M.D. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses."

Kymriah, developed by Novartis, is designed to cure some forms of acute lymphoblastic leukemia - but comes with a high price tag of $475,000.
In this recent Forbes article, oncologist Dr. Stuart Goldberg weighs in on whether insurers, drug developers, and health providers can work together to promote practice patterns that are both cost-effective and lifesaving for patients.